Related Experiment Videos
Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer
Shuang-Ta Xu1, Jian-Hua Xu1, Zheng-Rong Zheng1
1Breast and Thyroid Surgery Department, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, Fujian Province, China.
Abstract:
Triple-negative breast cancer (TNBC) is a complex breast cancer subtype characterized by the absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2). Long non-coding RNA (lncRNA) antisense non-coding RNA in the INK4 locus (ANRIL) has been verified as oncogenic molecular in series of tumors, however, the role of ANRIL in TNBC carcinogenesis is still unclear. The purpose of present study is to investigate the expression and in-depth regulation of ANRIL on TNBC tumorigenesis. Expression level of ANRIL was up-regulated in TNBC tumor tissue and cell lines compared to noncancerous tissue and non-TNBC cells. Besides, the up-regulated ANRIL expression was closely correlated to poor prognosis. In vitro, loss-of-function experiments showed that ANRIL knockdown interfered by interference oligonucleotide could markedly suppress TNBC cells proliferation and enhance apoptosis. In vivo, ANRIL knockdown inhibited the tumor growth. Bioinformatics analysis and luciferase reporter assay revealed that miR-199a targeted ANRIL at 3'-UTR. Rescue experiments showed that miR-199a inhibitor could reverse the tumor-suppressing role of ANRIL knockdown on TNBC proliferation and apoptosis. Overall, present study demonstrated that ANRIL overexpression modulated TNBC tumorigenesis through acting as molecular 'sponge' for miR-199a, providing a novel insight and therapeutic target for TNBC.
Insights
Long non-coding RNA ANRIL is overexpressed in triple-negative breast cancer (TNBC), promoting tumor growth. Inhibiting ANRIL or targeting its interaction with miR-199a suppressed TNBC progression, offering new therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Triple-negative breast cancer (TNBC) lacks standard therapeutic targets like ER, PR, and Her2.
- Long non-coding RNA (lncRNA) ANRIL is implicated in various cancers, but its role in TNBC is not well understood.
Purpose of the Study:
- To investigate the expression and regulatory mechanisms of ANRIL in TNBC tumorigenesis.
- To explore ANRIL as a potential therapeutic target for TNBC.
Main Methods:
- Quantitative real-time PCR to assess ANRIL expression in TNBC tissues and cell lines.
- In vitro loss-of-function studies (ANRIL knockdown) and in vivo tumor xenograft models.
- Bioinformatics analysis, luciferase reporter assays, and rescue experiments to elucidate the ANRIL-miR-199a interaction.
Main Results:
- ANRIL expression was significantly upregulated in TNBC tissues and cell lines, correlating with poor prognosis.
- ANRIL knockdown suppressed TNBC cell proliferation, induced apoptosis, and inhibited tumor growth in vivo.
- ANRIL directly targets miR-199a, and miR-199a inhibition reversed the anti-tumor effects of ANRIL knockdown.
Conclusions:
- ANRIL acts as an oncogene in TNBC by sponging miR-199a, promoting tumorigenesis.
- Targeting ANRIL or its interaction with miR-199a represents a promising therapeutic strategy for TNBC.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
MicroRNAs
MicroRNAs
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...